The quinolines PK 8165 and PK 9084 possess benzodiazepine-like activity in vitro but not in vivo.
The quinolines PK 8165 and PK 9084 bind to brain benzodiazepine receptors in vitro. However, unlike diazepam, these molecules do not reduce GABA turnover, possess anxiolytic properties, or displace [3H]flunitrazepam from benzodiazepine receptors in vivo. The pharmacological properties of PK 8165 and PK 9084 in vivo are thus unrelated to the benzodiazepine receptor.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001569:Benzodiazepines / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D003975:Diazepam / Q000494:pharmacology; D005445:Flunitrazepam / Q000378:metabolism; D066298:In Vitro Techniques; D051379:Mice; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid / Q000096:biosynthesis
D014151:Anti-Anxiety Agents; D011804:Quinolines; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; C030079:PK 9084; C030078:pipequaline; D003975:Diazepam